Related references
Note: Only part of the references are listed.Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma
Kuang-Tai Kuo et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma - Tissue effect predicts clinical response
Milind Javle et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2008)
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line
R. N. Keswani et al.
DISEASES OF THE ESOPHAGUS (2008)
Expression of prostaglandin E synthase in Barrett's cancer
B. H. A. von Rahden et al.
DISEASES OF THE ESOPHAGUS (2008)
Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Cetuximab with concurrent chemoradiation for esophagogastric cancer:: In regard to Safran et al. (Int J Radiat Oncol Biol Phys 2008;70:391-395)
Antoine Adens et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Joel Tepper et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer - Phase II Results from the North Central Cancer Treatment Group (N044B)
Aminah Jatoi et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway
Mercedes Lioni et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
M van Heijl et al.
BMC Surgery (2008)
Carcinogenetic impact of ADH1B and ALDH2 genes on squamous cell carcinoma risk of the esophagus with regard to the consumption of alcohol, tobacco and betel quid
Chien-Hung Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
A phase II study of gefitinib monotherapy in advanced Esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response
David R. Ferry et al.
CLINICAL CANCER RESEARCH (2007)
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
Y. Kawaguchi et al.
BRITISH JOURNAL OF CANCER (2007)
Secondary chemoprevention of Barrett's esophagus with celecoxib: Results of a randomized trial
Elisabeth I. Heath et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer
S. J. Dawson et al.
INVESTIGATIONAL NEW DRUGS (2007)
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Novel targeted therapies for advanced esophageal cancer
C.-C. Lin et al.
DISEASES OF THE ESOPHAGUS (2007)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Henk. M. W. Verheul et al.
NATURE REVIEWS CANCER (2007)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma:: a tissue microarray study
R. Langer et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
ML Janmaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma
M Younes et al.
EUROPEAN JOURNAL OF CANCER (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study
MC Dobelbower et al.
ANTI-CANCER DRUGS (2006)
Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection
EW Steyerberg et al.
GASTROINTESTINAL ENDOSCOPY (2005)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer
L Gibault et al.
BRITISH JOURNAL OF CANCER (2005)
Systemic treatment for oesophageal cancer
E van Meerten et al.
EUROPEAN JOURNAL OF CANCER (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial
MYV Homs et al.
LANCET (2004)
Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: A phase I study
H Safran et al.
CANCER INVESTIGATION (2004)
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus
JBF Hulscher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
NC Tebbutt et al.
ANNALS OF ONCOLOGY (2002)
Improved survival in both histologic types of oesophageal cancer in Sweden
M Sundelöf et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin, and PV15-FU in advanced esophagogastric cancer
P Ross et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Barrett's esophagus
SJ Spechler
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Epidemiology of Barrett's esophagus and adenocarcinoma
AJ Cameron
DISEASES OF THE ESOPHAGUS (2002)
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries
AAM Botterweck et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2000)
The recurrence pattern of esophageal carcinoma after transhiatal resection
JBF Hulscher et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2000)
Share Paper
